Lenalidomide Capsule
Product Images NDC 82293-009

This text provides information about a medication called Lenalidomide in capsule form, with a warning about potential human birth defects. It includes dosage instructions, storage conditions, and the importance of keeping the medication out of reach of children. The text also mentions the distribution by Novugen Pharma (USA) LLC and provides details about the manufacturer in India. Additionally, it highlights the need for dispensing a medication guide to each patient.*

This text is a label for Lenalidomide capsules, warning about potential birth defects and advising to dispense a Medication Guide to each patient. Each capsule contains 15 mg of Lenalidomide, with dosing information available in the prescribing information. The capsules should be stored at 20-25°C, with excursions permitted up to 15-30°C. The manufacturer is Novugen Pharma (USA) LLC, with distribution from Princeton, NJ. Additional details include guidelines for keeping the medicine out of reach of children, manufacturing location in India, and batch information for tracking purposes.*

This is information about Lenalidomide capsules with the NDC 82293-006-10. The medication is used under prescription with a warning about potential human birth defects. Pharmacists are instructed to dispense a Medication Guide to each patient. The usual dosage for this medication is 5mg, but patients should refer to the prescribing information for specific dosing and administration instructions. The capsules should be stored at temperatures between 20°C to 25°C (68°F to 77°F) with excursions permitted to 15°C to 30°C (59°F to 86°F). The product should be kept out of reach of children. The medication is distributed by Novugen Pharma (USA) LLC, and it is made in India. Additionally, the label contains batch details, a unique serial number, and a 2D data matrix printed during the packing process.*

This text provides information about Lenalidomide capsules, including a warning about potential human birth defects. Pharmacists are advised to dispense the accompanying Medication Guide to each patient. The typical dosage instructions are available in the prescribing information. The medication should be stored at a temperature range of 20°C to 25°C. The distributor is Novugen Pharma (USA) LLC located in Princeton, NJ, USA, and the product is manufactured in India. The text also mentions details about the packaging process and labeling for the product.*

The text is a label for Lenalidomide capsules (0.25mg per capsule). It includes a warning about the potential for human birth defects. There is guidance for pharmacists to dispense the medication guide to each patient and information about storage conditions. The medication is distributed by Novugen Pharma (USA) LLC and is made in India. Batch details and a unique serial number are mentioned to be printed on each label/carton during packing.*

The text describes a medication called Lenalidomide in capsule form. It provides a warning about the potential for human birth defects and instructs pharmacists to dispense a Medication Guide to each patient. The usual dosage information is available in the prescribing information. The storage conditions for the medication and details about keeping it out of reach of children are also provided. The medication is distributed by Novugen Pharma (USA) LLC and includes batch details along with variable data and a unique serial number printed on each label/carton during packing.*

This evaluated text provides information on survival probability (%) over time for different treatment methods. It compares survival rates between treatments such as Rd Continuous, Rd18, and MPT. The text also includes overall survival data in months and the number of subjects at risk for each treatment group. The outcomes indicate the percentage of events for each treatment method, providing insights into their effectiveness in terms of survival rates.*

This text provides data on survival probability and progression-free survival comparing Lenalidomide to Placebo. The information includes the number of subjects at risk, percentage of PFS events, and time in months for each group. The study indicates that Lenalidomide may have a higher survival probability and longer progression-free survival compared to Placebo.*

This statistical data is showing the proportion of subjects in a study, with HR (Hazard Ratio) of 0.285 and confidence interval of 0.210 to 0.366, indicating a statistically significant difference in progression between the two groups. The groups compared are Lenadinomide/Dex and Placebo/Dex, with Time to Progression measured in months. The study demonstrates a significant difference in progression rates between these two treatment groups.*

This is a statistical analysis of the proportion of subjects in two different treatment groups with a comparison of their hazard ratio (HR) and 95% confidence interval (CI). The study shows a statistically significant difference between the treatments with a p-value of less than 0.001, indicating that Lenalidomide/Dex group has a significantly lower risk of progression compared to the Placebo/Dex group over a period of 15 months.*

This text presents a comparison of two treatment groups: 1) Rituximab + Lenalidomide and 2) Rituximab + Placebo, showing data on progression-free survival over several months. The results indicate a statistically significant difference between the two groups, with the P-value for the Long Rank test being less than 0.0001. The table displays the number of subjects at risk at various time points, showing a decline in the number of individuals as time progresses.*